Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | IDH1 mutant |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05052957 | Phase II | Carmustine + Filgrastim + O6-benzylguanine + Temozolomide | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM) | Recruiting | USA | 0 |
NCT06095375 | Phase I | Regorafenib + Temozolomide | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) | Active, not recruiting | ITA | 0 |
NCT03047993 | Phase Ib/II | Azacitidine + Telaglenastat | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT04555577 | Phase I | Peposertib Temozolomide | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | Recruiting | USA | 0 |
NCT05188508 | Phase II | Olaparib + Pembrolizumab + Temozolomide | Pembrolizumab, Olaparib, and Temozolomide for People with Glioma | Recruiting | USA | 0 |
NCT05218408 | Phase Ib/II | Cyclophosphamide + Fludarabine CYNK-001 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) | Withdrawn | 0 | |
NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Completed | DEU | 0 |
NCT04559230 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT03878095 | Phase II | Ceralasertib + Olaparib | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | Active, not recruiting | USA | 0 |
NCT06636162 | Phase I | DSP-0390 | Window of Opportunity Study of DSP-0390 in Gliomas | Not yet recruiting | USA | 0 |
NCT02632708 | Phase I | Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | Active, not recruiting | USA | NLD | DEU | 0 |
NCT02428855 | Phase II | Dasatinib | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | Completed | USA | 0 |
NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05627323 | Phase I | CHM-1101 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Active, not recruiting | USA | 0 |
NCT04118036 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib + Pembrolizumab In Glioblastoma | Withdrawn | USA | 0 |
NCT06831526 | Phase I | Azeliragon + Temozolomide | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | Not yet recruiting | USA | 0 |
NCT03701295 | Phase Ib/II | Azacitidine + Pinometostat | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | Completed | USA | 0 |
NCT04629209 | Phase II | ONC201 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | Withdrawn | USA | 0 |
NCT02981940 | Phase II | Abemaciclib | A Study of Abemaciclib in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT06776250 | Phase II | Tarlatamab | Study of How Safe and Effective Tarlatamab is in Brain Cancers | Not yet recruiting | CAN | 0 |
NCT05743595 | Phase I | Personalized cancer vaccine + Retifanlimab | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Recruiting | USA | 0 |
NCT05283109 | Phase I | P30-EPS + Poly ICLC | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) | Recruiting | USA | 0 |
NCT03557359 | Phase II | Nivolumab | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | Active, not recruiting | USA | 0 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT04195555 | Phase II | Ivosidenib | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | AUS | 1 |
NCT05376800 | Phase I | BI 907828 | A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma | Active, not recruiting | USA | ESP | BEL | 0 |
NCT05766514 | Phase II | Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | Not yet recruiting | USA | 0 |
NCT05345002 | Phase II | Retifanlimab + Tretinoin | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Recruiting | USA | 0 |
NCT05417594 | Phase Ib/II | AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | SWE | GBR | ESP | DEU | AUS | 1 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
NCT05222802 | Phase I | ERAS-801 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Active, not recruiting | USA | 0 |
NCT04764474 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | Recruiting | USA | ESP | 0 |
NCT04945148 | Phase II | Metformin + Temozolomide | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) | Recruiting | ITA | FRA | 0 |
NCT02989857 | Phase III | Ivosidenib | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | Completed | USA | ITA | GBR | FRA | ESP | 1 |
NCT05326464 | Phase III | Tofacitinib | Tofacitinib in Recurrent GBM Patients | Recruiting | USA | 0 |
NCT06478212 | Phase Ib/II | Temozolomide + Vorasidenib | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT | 2 |
NCT06291987 | Phase I | Ivosidenib + Ruxolitinib | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) | Recruiting | USA | 0 |
NCT05183204 | Phase II | GDC-0084 + Metformin | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | Recruiting | USA | 0 |
NCT06258018 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) | Not yet recruiting | ITA | 0 |
NCT02858895 | Phase II | MDNA55 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | Completed | USA | 0 |
NCT04396860 | Phase II | Temozolomide Ipilimumab + Nivolumab | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT05180825 | Phase II | Vinblastine Trametinib | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC) | Recruiting | FRA | 0 |
NCT03718767 | Phase II | Nivolumab | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | Active, not recruiting | USA | 0 |
NCT02492737 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | Completed | USA | FRA | 0 |
NCT06543381 | Phase I | Olutasidenib | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | Recruiting | USA | 0 |
NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib W TMZ for RGBM | Recruiting | USA | 0 |
NCT03430791 | Phase II | Ipilimumab + Nivolumab Nivolumab | Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Terminated | USA | 0 |
NCT03749187 | Phase I | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) | Recruiting | USA | 0 |
NCT06297512 | Phase II | Doxorubicin + Temozolomide | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | Recruiting | ITA | 0 |
NCT03922555 | Phase I | Decitabine and Cedazuridine | ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | Recruiting | USA | 0 |
NCT06597734 | Phase II | Decitabine and Cedazuridine + Olutasidenib Azacitidine + Olutasidenib Decitabine + Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | Recruiting | USA | 0 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT06566742 | Phase II | Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | Recruiting | USA | 0 |
NCT02073994 | Phase I | Ivosidenib | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | Completed | USA | FRA | 0 |
NCT02677922 | Phase Ib/II | Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | Active, not recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 2 |
NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Suspended | USA | NZL | CAN | AUS | 0 |
NCT03212274 | Phase II | Olaparib | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | 0 |
NCT03127735 | Phase I | BAY1436032 | BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) | Completed | USA | DEU | 0 |
NCT04729959 | Phase II | Atezolizumab + Tocilizumab | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT05406700 | Phase I | Niraparib | Niraparib In Recurrent IDH 1/2 Gliomas | Recruiting | USA | 0 |
NCT04278781 | Phase II | Ivosidenib | AG-120 in People With IDH1 Mutant Chondrosarcoma | Active, not recruiting | USA | 0 |
NCT02481154 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Completed | USA | 0 |
NCT06719362 | Phase I | M3T01 M3T01 + Temozolomide M3T01 + Pembrolizumab Fluorouracil + Leucovorin + M3T01 + Oxaliplatin + Pembrolizumab | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | Not yet recruiting | USA | 0 |
NCT03173248 | Phase III | Azacitidine Azacitidine + Ivosidenib | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) | Active, not recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUT | AUS | 6 |
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT05474378 | Phase I | Retroviral vector transduced B7-H3 CAR T cells | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | Active, not recruiting | USA | 0 |
NCT05879120 | Phase II | Pembrolizumab | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Active, not recruiting | USA | 0 |
NCT05432804 | Phase Ib/II | Selinexor + Temozolomide Temozolomide | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | Recruiting | USA | 0 |
NCT05401097 | Phase II | Azacitidine + Enasidenib + Venetoclax Azacitidine + Ivosidenib + Venetoclax | IDH Targeted/non- Targeted Vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | Recruiting | USA | 0 |
NCT04955938 | Phase I | Enasidenib + Fedratinib Fedratinib + Ivosidenib | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | Withdrawn | USA | 0 |
NCT03991832 | Phase II | Durvalumab + Olaparib | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID) | Recruiting | CAN | 0 |
NCT03139916 | Phase II | Bavituximab + Temozolomide | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT02525692 | Phase II | ONC201 | Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | Terminated | USA | 0 |
NCT04762602 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations | Active, not recruiting | USA | ESP | 0 |
NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 4 |
NCT05756777 | Phase I | Gilteritinib + Ivosidenib Enasidenib + Gilteritinib | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT06668584 | Phase Ib/II | Olutasidenib | A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients with IDH1-mutated Myeloid Malignancies | Recruiting | USA | 0 |
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Completed | USA | 0 |
NCT02968940 | Phase II | Avelumab | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Completed | USA | 0 |
NCT02576444 | Phase II | Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib | OLAParib COmbinations (OLAPCO) | Terminated | USA | 0 |
NCT03503409 | Phase II | Ivosidenib | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | Active, not recruiting | ITA | FRA | 0 |
NCT06413706 | Phase II | Abemaciclib + Temozolomide Temozolomide | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Recruiting | USA | ROU | NLD | ITA | FRA | ESP | DNK | BEL | AUS | 1 |
NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Recruiting | USA | CAN | 0 |
NCT06455605 | Phase Ib/II | 2141 V-11 + D2C7-IT | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | Recruiting | USA | 0 |
NCT04774393 | Phase Ib/II | Decitabine and Cedazuridine + Ivosidenib + Venetoclax Decitabine and Cedazuridine + Enasidenib + Venetoclax | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05588141 | Phase Ib/II | Zotiraciclib | A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | Recruiting | USA | 0 |
NCT04015700 | Phase I | GNOS-PV01 + Rocakinogene sifuplasmid | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT05432375 | Phase I | Tinostamustine | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Active, not recruiting | ESP | CHE | 0 |